The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B‐Cell Lymphoma (CLSG‐CNS‐01): A Randomized, Multicenter, Prospective Phase 3 Trial
Hematological Oncology · 2026
DOI: 10.1002/hon.70193 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hematological Oncology, 2026. Verfasst von H Mocikova und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Fakultni Nemocnice Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Methotrexate, Central Nervous System Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky, the Cooperatio Program, research area "Oncology and Haematology".
Abstract (Originalsprache)
The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B‐cell lymphoma (DLBCL). Treatment consisted of six cycles of R‐CHOP + 2xR or DA‐EPOCH‐R + 2xR. Patients with intermediate or high‐risk CNS International Prognostic Index (CNS‐IPI) were randomized to receive CNS prophylaxis with either 2 doses of MTX 3 g/m 2 i.v. (arm A) or 6 doses of MTX 12 mg i.t. (arm B). Patients with low‐risk CNS‐IPI did not receive MTX prophylaxis (arm C). The primary objective was to compare the cumulative incidence of CNS relapse between arms A and B. Secondary objectives included evaluation of overall response rate (ORR), complete remission rate (CRR), progression‐free survival (PFS), overall survival (OS), and treatment‐related safety across all arms. Between 7/2015 and 5/2024, a total of 100 patients were enrolled: 30 in arm A, 31 in arm B, and 39 in arm C. ORR did not differ among arms ( p = 0.20). During a median follow‐up of 54.9 months, CNS relapses were observed in three patients who had received MTX prophylaxis‐one in arm A and two in arm B. The 5‐year cumulative incidence of CNS relapse was 0% in arm A and 8.7% in arm B ( p = 0.72). However, due to the small sample size, the primary endpoint results are inconclusive. Median PFS was comparable between arms A and B (HR 0.66, p = 0.20). MTX i.v. was associated with a significantly higher grade ≥ 3 neutropenia ( p = 0.0003) and infection ( p = 0.0063). The higher infection rate contributed to a worse 5‐year OS in arm A versus B (47.2% vs. 72.4%, HR 0.46, p = 0.04). Conclusion: our trial faced limitations due to a low number of randomized participants, making the interpretation of results challenging. A larger, international randomized trial is necessary to determine the benefit of CNS prophylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology, Fakultni Nemocnice Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- Department of Clinical Hematology, University Hospital, Pilsen, Czech Republic.
- Department of Internal Medicine- Hematology, University Hospital and Faculty of Medicine, Pilsen, Czech Republic.
- Cell Therapy Department, Institute of Haematology and Blood Transfusion, Prague, Czech Republic.
- Ist Department of Medicine, General University Hospital, Ist Faculty of Medicine, Charles University, Prague, Czech Republic.
ORCID-Profile: M Trneny
Förderung
- Ministerstvo Zdravotnictví Ceské Republiky
- the Cooperatio Program, research area "Oncology and Haematology"
Zitieren
APA
Mocikova, H., Gaherova, L., Jancarkova, T., Suri, A., Janikova, A., Steinerova, K., Belada, D., Pytlik, R., Duras, J., Trnkova, M., Blahovcova, P., Kozak, T., & Trneny, M. (2026). The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B‐Cell Lymphoma (CLSG‐CNS‐01): A Randomized, Multicenter, Prospective Phase 3 Trial. Hematological Oncology. https://doi.org/10.1002/hon.70193
Vancouver
Mocikova H, Gaherova L, Jancarkova T, Suri A, Janikova A, Steinerova K, et al. The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B‐Cell Lymphoma (CLSG‐CNS‐01): A Randomized, Multicenter, Prospective Phase 3 Trial. Hematological Oncology. 2026. doi:10.1002/hon.70193
BibTeX
@article{Mocikova2026,
author = {Mocikova, H and Gaherova, L and Jancarkova, T and Suri, A and Janikova, A and Steinerova, K and Belada, D and Pytlik, R and Duras, J and Trnkova, M and Blahovcova, P and Kozak, T and Trneny, M},
title = {The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B‐Cell Lymphoma (CLSG‐CNS‐01): A Randomized, Multicenter, Prospective Phase 3 Trial},
journal = {Hematological Oncology},
year = {2026},
doi = {10.1002/hon.70193}
}
EUVIMED